Shots:
The CHMP has recommended approval of mCOMBRIAX (mRNA-1083), a combination vaccine for prevention of influenza and COVID-19 in patients ≥50 yrs. If granted, the approval would be valid in all 30 EEA states
Opinion was based on a P-III trial evaluating mRNA-1083 in ~8,000 adults across two cohorts: ≥65yrs (n~4,000) vs co-administered Fluzone High‑Dose / Efluelda + Spikevax and 50–64yrs (n~4,000) vs Fluarix + Spikevax, where…
Shots:
Driven by a noble pursuit to ensure global health security, vaccines cater to the healthcare needs of millions and billions of people. With an instrumental role in containing the COVID-19 pandemic, immunization prevents more than 5 million deaths annually from conditions like diphtheria, tetanus, pertussis, influenza, and measles
With a global market size of…

